One preclinical study showed that blocking the IL-33/suppression of tumorigenicity 2 (ST2, also known as IL-1RL1) signaling axis enhances mucosal healing in DSS- and 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis in mice [206,207,208]. This evidence concerns the gene IL1RL1 and colitis.